Urinary Albumin Excretion in Patients With Diabetes After Renal Transplantation

Transplantation Proceedings

Volumn 38, Issue 9, 2006, Pages 2879-2882

  Hor, T ^a   Baldwin, D ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CADAVER DONOR; CADAVER KIDNEY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; DATA ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZATION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ALBUMINURIA; CADAVER; DIABETES MELLITUS; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE DONORS;

EID: 33750943805     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.094     Document Type: Article

References (15)

1. Cosio F.G., Pesavento T.E., Kin S., et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62 (2002) 1440
2. Montori V.M., Velosa J.A., Basu A., et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 25 (2002) 583
3. Kasiske B.L., Vazquez M.A., Harmon W.E., et al., American Society of Transplantation. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11 (2000) S1
4. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 75 (2003) SS3
5. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2004), National Institutes of Heath, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD [NIH Publication No. 26- 5-2005]
6. Caramori M.L., Fioretto P., and Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?. Diabetes 49 (2000) 1399
7. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47 (1995) 1703
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703
9. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329 (1993) 1456
10. Barnett A.H., Bain S.C., Bouter P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (2004) 1952
11. The American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 suppl 1 (2006) S4
12. Garg J.P., and Bakris G.L. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7 (2002) 35
13. Zaltzman J.S., Nash M., Chiu R., et al. The benefits of rennin-angiotensin blockade in renal transplant recipients with proven allograft nephropathy. Nephrol Dial Transplant 19 (2004) 940
14. Kim W., Lee S., Kang S.K., et al. Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist therapy in hypertensive renal transplant recipients. Transplant Proc 34 (2002) 3223
15. Montanaro D., Gropuzzo M., Tulissi P., et al. Renal allograft protection with early angiotensin-converting enzyme inhibitor administration. Transplant Proc 36 (2004) 692